List of Bethkis drug patents
Bethkis is owned by Chiesi.
Bethkis contains Tobramycin.
Bethkis has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Bethkis are:
- US7939502
- US6987094
- US7696178
Bethkis was authorised for market use on 12 October, 2012.
Bethkis is available in solution;inhalation dosage forms.
Bethkis can be used as management of cystic fibrosis patients.
The generics of Bethkis are possible to be released after 22 September, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939502 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Jun, 2022
(7 months ago) | |
| US6987094 | CHIESI | Optimized formulation of tobramycin for aerosolization |
Sep, 2022
(4 months ago) | |
| US7696178 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Sep, 2022
(4 months ago) | |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 12 October, 2012
Treatment: Management of cystic fibrosis patients
Dosage: SOLUTION;INHALATION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic